Business Description
HeXun Biosciences Co Ltd
ISIN : TW0006986003
Total Employee Number:
35Description
HeXun Biosciences Co Ltd is engaged in the research and development of cell drugs and cell derivatives. It conducts research and development jointly with medical research institutions to use stem cells to treat cardiovascular, immune-inflammatory, and neurodegenerative diseases to develop innovative cell drugs and treatment methods. The company's main business items are new drug research and development, biotechnology services, and research and development services, such as: commissioned research and development and production services for cell medicine, agency testing and development services, and biomedical consulting services, etc.
Financial Strength
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 23.91 | |||||
Equity-to-Asset | 0.91 | |||||
Debt-to-Equity | 0.03 | |||||
Debt-to-EBITDA | 0.2 | |||||
Interest Coverage | 122.82 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | 13.82 | |||||
Beneish M-Score | -2.87 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 69 | |||||
3-Year EBITDA Growth Rate | 124.9 | |||||
3-Year FCF Growth Rate | 122.3 | |||||
3-Year Book Growth Rate | 27.6 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 9.94 | |||||
9-Day RSI | 19.78 | |||||
14-Day RSI | 25.47 | |||||
3-1 Month Momentum % | -24.63 | |||||
6-1 Month Momentum % | -17.64 | |||||
12-1 Month Momentum % | -34.06 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 12.14 | |||||
Quick Ratio | 12.01 | |||||
Cash Ratio | 10.51 | |||||
Days Inventory | 125.44 | |||||
Days Sales Outstanding | 90.76 | |||||
Days Payable | 43.88 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Dividend Yield % | 0.46 | |||||
Forward Dividend Yield % | 0.46 | |||||
5-Year Yield-on-Cost % | 0.46 | |||||
3-Year Average Share Buyback Ratio | -4.3 | |||||
Shareholder Yield % | 0.38 |
Profitability Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 90.97 | |||||
Operating Margin % | 42.36 | |||||
Net Margin % | 37.74 | |||||
EBITDA Margin % | 56.1 | |||||
FCF Margin % | 43.04 | |||||
OCF Margin % | 53.14 | |||||
ROE % | 14.65 | |||||
ROA % | 13.09 | |||||
ROIC % | 37.79 | |||||
3-Year ROIIC % | 134.15 | |||||
ROC (Joel Greenblatt) % | 74.43 | |||||
ROCE % | 17.22 | |||||
Years of Profitability over Past 10-Year | 3 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 16.61 | |||||
PE Ratio without NRI | 16.61 | |||||
Price-to-Owner-Earnings | 14.6 | |||||
PS Ratio | 6.27 | |||||
PB Ratio | 2.03 | |||||
Price-to-Tangible-Book | 2.07 | |||||
Price-to-Free-Cash-Flow | 14.64 | |||||
Price-to-Operating-Cash-Flow | 11.83 | |||||
EV-to-EBIT | 9.7 | |||||
EV-to-EBITDA | 7.97 | |||||
EV-to-Revenue | 4.48 | |||||
EV-to-FCF | 10.64 | |||||
Price-to-GF-Value | 0.38 | |||||
Price-to-Graham-Number | 1.24 | |||||
| Price-to-Net-Current-Asset-Value | 2.57 | |||||
| Price-to-Net-Cash | 3.02 | |||||
Earnings Yield (Greenblatt) % | 10.31 | |||||
FCF Yield % | 6.1 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
HeXun Biosciences Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil NT$) | 308.212 | ||
| EPS (TTM) (NT$) | 2.51 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | 35.46 | ||
| 14-Day RSI | 25.47 | ||
| 14-Day ATR (NT$) | 1.051457 | ||
| 20-Day SMA (NT$) | 43.2925 | ||
| 12-1 Month Momentum % | -34.06 | ||
| 52-Week Range (NT$) | 40.7 - 71.6 | ||
| Shares Outstanding (Mil) | 52.13 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
HeXun Biosciences Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
HeXun Biosciences Co Ltd Stock Events
| Event | Date | Price (NT$) | ||
|---|---|---|---|---|
| TWD 0.194115 Cash Dividend | 2026-08-18 | 43.00 (-1.83%) |
Show
Entries
HeXun Biosciences Co Ltd Frequently Asked Questions
What is HeXun Biosciences Co Ltd(ROCO:6986)'s stock price today?
The current price of ROCO:6986 is NT$41.70. The 52 week high of ROCO:6986 is NT$71.60 and 52 week low is NT$40.70.
When is next earnings date of HeXun Biosciences Co Ltd(ROCO:6986)?
The next earnings date of HeXun Biosciences Co Ltd(ROCO:6986) is .
Does HeXun Biosciences Co Ltd(ROCO:6986) pay dividends? If so, how much?
The Dividend Yield %  of HeXun Biosciences Co Ltd(ROCO:6986) is 0.46% (As of Today), Highest Dividend Payout Ratio of HeXun Biosciences Co Ltd(ROCO:6986) was 0. The lowest was 0. And the median was 0. The  Forward Dividend Yield % of HeXun Biosciences Co Ltd(ROCO:6986) is 0.46%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on HeXun Biosciences Co Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers